LLGLX | SFCWX | LLGLX / SFCWX | |
Total Expense Ratio | 1.05 | 0.65 | 162% |
Annual Report Gross Expense Ratio | 1.29 | 0.65 | 198% |
Fund Existence | 13 years | 9 years | - |
Gain YTD | 11.787 | 9.923 | 119% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 10000 | 1000000 | 1% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 259M | 80.3B | 0% |
Annual Yield % from dividends | 2.92 | 0.94 | 310% |
Returns for 1 year | 14.18 | 10.67 | 133% |
Returns for 3 years | 32.12 | 22.71 | 141% |
Returns for 5 years | 26.21 | 17.32 | 151% |
Returns for 10 years | 48.27 | N/A | - |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
FPHAX | 24.89 | 0.35 | +1.43% |
Fidelity Select Pharmaceuticals Port | |||
ETCEX | 12.80 | N/A | N/A |
Eventide Exponential Technologies C | |||
QILGX | 41.30 | N/A | N/A |
Federated Hermes MDT Large Cap Growth IS | |||
OIEIX | 25.09 | -0.07 | -0.28% |
JPMorgan Equity Income A | |||
LSRCX | 1.85 | -0.02 | -1.07% |
Lord Abbett Small Cap Value C |